TriangleLadarixin + Sotorasib (NCT05815173)
Ladarixin + Sotorasib trial for Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer (NCT05815173). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced non-small cell lung cancer that carries a KRAS G12C mutation.
The idea: add ladarixin, an experimental pill, to sotorasib, an approved targeted drug for this mutation. Both are taken by mouth, in 21 day cycles. The ladarixin dose is raised step by step in small groups of patients.
This phase 1 study plans 40 patients and first looks at dose-limiting side effects. At NYU Langone Health in New York, Salman Punekar leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.